ORIGINAL ARTICLE

Intracellular cyclic adenosine monophosphate regulates the efficiency of intercellular transmission of human T-lymphotropic virus type I

Tatsufumi Nakamura,[1] Katsuya Satoh,[1] Hideki Nakamura[2] and Hironori Yamasaki[3]

[1]Department of Molecular Microbiology and Immunology, Nagasaki University, [2]Unit of Translational Medicine, Department of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University, [3]Center for Health and Community Medicine, Nagasaki University, Nagasaki, Japan

Abstract

Objective To investigate the relationship between the intercellular transmission efficiency of human T-lymphotropic virus type I (HTLV-I) and the signaling involved in actin polymerization during cytoskeletal reorganization in a comparative study of HTLV-I-infected T-cell lines derived from an HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patient or an HTLV-I carrier.

Methods HCT-5 and TL-Su cells derived from an HAM/TSP patient and an HTLV-I carrier, respectively, were used as HTLV-I-infected T-cell lines. After co-cultivation of each HTLV-I-infected T-cell line with H9/K30 *luc* reporter cells, the relative luc activities were calculated to analyze the efficiency of intercellular transmission of HTLV-I. The intracellular levels of cyclic adenosine monophosphate (cAMP) or cyclic guanosine monophosphate (cGMP) were measured in enzyme-linked immunoassays. The expression of phosphorylated vasodilator-stimulated phosphoprotein (p-VASP) was analyzed by western blotting.

Results Treatment of HCT-5 cells with latrunculin B, an inhibitor of actin polymerization, significantly suppressed the relative luc activity. Western blotting analysis of HCT-5 cells treated with the adenylyl cyclase activator forskolin showed upregulation of p-VASP, with a concomitant and significant increase in the intracellular cAMP concentration. Furthermore, the relative luc activity was significantly decreased. The intracellular cAMP, but not cGMP levels, were significantly lower in HCT-5 than in TL-Su. Vasodilator-stimulated phosphoprotein appeared less phosphorylated in HCT-5 than in TL-Su. The relative luc activity was significantly higher in HCT-5 than in TL-Su.

Conclusions The intracellular cAMP concentration regulates the efficiency of intercellular HTLV-I transmission under the control of p-VASP expression, suggesting the intercellular transmission potential of HTLV-I-infected T cells of HAM/TSP patients is enhanced by downregulated intracellular cAMP levels. (Clin. Exp. Neuroimmunol. doi: 10.1111/cen3.12097, February 2014)

Introduction

Human T-lymphotropic virus type I (HTLV-I) infects cells by intercellular transmission through the virological synapse, which is composed of integrin/ligand complexes, such as lymphocyte function antigen-1 (αLβ2)/intercellular adhesion molecule-1 (ICAM-1), and mediates cytoskeletal polarization.[1–3] Integrin/ligand signaling induces the activation of small GTPases, such as Rho, Rac and Cdc42, and subsequently regulates cytoskeletal reorganization including actin polymerization, cell polarity and reorientation of the microtubule-organizing center.[4–6] Therefore, it can be speculated that the status of

cytoskeletal reorganization determines the intercellular transmission efficiency of HTLV-I. We previously reported that Rac and Cdc42 are more activated in HTLV-I-infected T-cell lines derived from HAM/TSP patients than in those derived from other origins,[7] suggesting that HTLV-I-infected T-cell lines derived from HAM/TSP patients have the potential of the efficient intercellular transmission of HTLV-I based on activated status of the cytoskeletal reorganization including actin polymerization.

The vasodilator-stimulated phosphoprotein (VASP) regulates signal transduction pathways involved in actin cytoskeleton dynamics.[8,9] VASP is a known substrate of serine/threonine kinases, such as cyclic adenosine monophosphate- (cAMP) or cyclic guanosine monophosphate (cGMP)-dependent protein kinase (PKA or PKG, respectively). Both kinases phosphorylate the Ser^{157} and Ser^{239} sites in VASP. It is known that phosphorylated VASP (p-VASP) acts as a negative regulator of actin dynamics. Phosphorylation of VASP catalyzed by either PKA or PKG inhibits actin polymerization, and conversely, dephosphorylation accelerates actin polymerization. That is, the degree of reorganization of the actin cytoskeleton is determined by the phosphorylated or dephosphorylated status of VASP. Therefore, the intracellular cAMP or cGMP concentration might regulate polarization of the actin cytoskeleton and affect the intercellular transmission efficiency of HTLV-I.

To test these hypotheses, we investigated the relationships between the intercellular transmission efficiency of HTLV-I, the intracellular cAMP or cGMP levels and the phosphorylation status of VASP in a comparative study of HTLV-I-infected T-cell lines derived from an HAM/TSP patient or an HTLV-I carrier.

Methods

Chemicals and antibodies

Latrunclin B was purchased from Enzo Life Sciences (Plymouth Meeting, PA, USA). Forskolin was purchased from Applichem (Darmstadt, Germany). Both compounds were dissolved with dimethyl sulfoxide (DMSO) as the vehicle before experiments. Rabbit polyclonal anti-VASP, phosphorylated VASP (Ser^{157} or Ser^{239}; p-VASP), rabbit monoclonal anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and horseradish peroxidase (HRP)-conjugated goat anti-rabbit immunoglobulin G antibody were purchased from Cell Signaling Technology (Beverly, MA, USA). Mouse monoclonal anti-HTLV-I tax or gp-46,

α-tubulin and an HRP-conjugated goat anti-mouse immunoglobulin G antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Cell lines

Interleukin-2 (IL-2)-dependent HTLV-I-infected T-cell line derived from the cerebrospinal fluid of an HAM/TSP patient (HCT-5) and IL-2-independent HTLV-I-infected T-cell line derived from an HTLV-I carrier (TL-Su) were used in the present study.[7]

The H9/K30 *luc* reporter cell line was kindly provided by Professor Akio Adachi (University of Tokushima Graduate School, Tokushima, Japan). H9/K30 *luc* cells are lymphocytic H9 cells that have been stably transfected with a plasmid containing the gene encoding luciferase under the control of the HTLV-I long terminal repeat (LTR).[10] Therefore, as activation of LTR driven by HTLV-I tax induces luciferase expression, these reporter cells can detect the efficiency of HTLV-I transmission under co-cultivation with HTLV-I-infected cells by a luciferase assay system. Expression of the integrin αLβ2 and its ligand, ICAM-1, was confirmed in both cell lines by flow cytometric analysis.

The present study complied with the guidelines of the ethics committee of our institution.

Western blotting analysis

Each culture of HTLV-I-infected T cells was collected and lysed by the addition of M-PER mammalian protein extraction reagent (Thermo Scientific, Hanover Park, IL, USA) supplemented with a protease inhibitor cocktail (Sigma-Aldrich, St, Louis, MO, USA) and a Halt phosphatase inhibitor cocktail (Thermo Scientific). Insoluble material was removed by centrifugation at 14 300 g for 30 min at 4°C, and the supernatant was analyzed by western blotting. An identical amount of protein for each lysate (20 μg) was subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (ATTO, Tokyo, Japan). Subsequently, proteins were transferred onto a polyvinylidene difluoride membrane and immersed in 5% non-fat milk in Tris-buffered saline, 0.1% Tween 20 (TBST) at room temperature for 60 min to block non-specific binding sites. Anti-p-VASP, -VASP, -HTLV-I tax and -HTLV-I gp46 (all used at 1:1000 dilution) antibodies were used as primary detection reagents. Anti-GAPDH or α-tubulin (both used at 1:1000 dilution) antibodies for detection of an internal control protein were used for confirmation of equal protein loading. Membranes were

incubated overnight with specific primary antibodies at 4°C. After washing with TBST, membranes were incubated with appropriate secondary HRP-conjugated anti-species antibodies at room temperature for 1 h. After further washing with TBST, peroxidase activity was detected by using the ECL plus western blot detection system (Amersham, GE Healthcare, Little Chalfont, UK).

Measurement of intracellular cAMP or cGMP levels

Intracellular cAMP or cGMP levels in both cell lines were measured using enzyme-linked immunoassay kits [cyclic AMP complete assay (Stressgen, Ann Arbor, MI, USA) or Paramete cyclic GMP assay (R&D systems, Minneapolis, MN, USA), respectively], according to the instructions provided by the manufacturer. Briefly, equal numbers of HCT-5 or TL-Su cells and equal numbers of DMSO- or forskolin-treated HCT-5 were lysed with an equal volume of lysis buffer. After uniform lysis was confirmed by microscopy, the cellular debris was removed by centrifugation at 600 g for 10 min at 4°C, and the supernatant was used for assays. The intracellular cAMP or cGMP levels were determined in triplicate. Data were expressed as mean ± SD. The minimum detection limits of cAMP and cGMP in these assays were 0.039 pmol/mL or 1.14 pmol/mL, respectively.

Co-cultivation

HCT-5 or TL-Su (5×10^5 cells) were co-cultivated with H9/K30 *luc* reporter cells (3.5×10^5 cells; kindly provided by Professor Akio Adachi, University of Tokushima Graduate School) in a 24-well culture plate at 37°C under 5% CO_2. After co-cultivation for 6 h, luciferase activity was assessed by using a luciferase assay system (Promega, Madison, WI, USA) and Gene Light (Microtec, Tokyo, Japan). The relative luc activity was calculated according to the following formula: relative luminescent units (RLU) of co-cultivated sample/RLU of the H9 only cultivated sample. Data were expressed as mean ± SD of triplicate cultures.

Latrunclin B and forskolin treatment

Latrunclin B disrupts the actin cytoskeleton of cells by inhibiting actin polymerization.[11] Forskolin induces increased intracellular cAMP levels by activation of adenylyl cyclase.[12] HCT-5 cells were treated with 1.25 µmol/L latrunculin B or 15 µmol/L forskolin or DMSO. Treated HCT-5 cells were lysed

at intervals up to 6 h for western blotting analysis and an assay of intracellular cAMP or cGMP levels. Concomitantly, after treatment for 90 min, HCT-5 cells were co-cultivated with H9/K30 *luc* cells. Analysis of cell viability using a modified MTT assay, MTS (Promega), showed that treatment with both compounds for up to 6 h was not associated with toxicity in either H9/K30 *luc* or HCT-5 cells.

Statistical analysis

Student's *t*-tests were used for statistical analysis. Differences were considered significant at $P < 0.05$.

Results

Effect of latrunculin B treatment on the intercellular transmission efficiency of HTLV-I

The relationship between the intercellular transmission efficiency of HTLV-I and actin polymerization was first analyzed. As shown in Fig. 1a, treatment of HCT-5 cells with latrunculin B significantly suppressed (approximately 70%) the relative luc activity (DMSO treated: 6.7 ± 0.3 *vs* latrunculin B treated: 2 ± 0.1, $P = 0.0014$) without downregulation of the expression of HTLV-I tax and gp46 (Fig. 1b). These observations suggest that actin reorganization plays


Figure 1 Effect of latrunculin B treatment on HCT-5 cells. HCT-5 cells treated with 1.25 µmol/L latrunculin B for 90 min (5×10^5 cells) were co-cultivated for 6 h with H9/K30 *luc* cells (3.5×10^5 cells) in a 24-well culture plate at 37°C in 5% CO_2. (a) Treatment with latrunculin B significantly suppressed (approximately 70%) the relative luc activity (dimethyl sulfoxide [DMSO] treated: 6.7 ± 0.3 *vs* latrunculin B treated: 2.0 ± 0.1, $P =$ (b) Latrunculin B treatment for up to 6 h did not affect the expression of human T-lymphotropic virus type I (HTLV-I) tax and gp46. Statistical significance was determined by Student's *t*-tests.

an important role in the intercellular transmission of HTLV-I.

Relationship between the intracellular cAMP concentration and the efficiency of the intercellular transmission of HTLV-I

Forskolin treatment of HCT-5 induced a significant increase in the intracellular cAMP concentration (DMSO treated, forskolin treated: 5.37 ± 0.47, 42.90 ± 0.95 pmol/mL, respectively, $P = 0.0047$; Fig. 2a). Concomitantly, upregulation of p-VASP (Ser[157]) was observed by western blotting analysis (Fig. 2b). However, there were no differences in the expression of HTLV-I tax and gp46 between DMSO and forskolin treatment (Fig. 2b). As shown in Fig. 2c, analysis of the intercellular transmission efficiency of HTLV-I revealed a decrease in relative luc activity to 50% in forskolin-treated HCT-5 (3 ± 0.5), compared with DMSO-treated HCT-5 cells (6 ± 0.9; $P = 0.0299$).

Comparative analysis of intracellular cAMP concentrations, p-VASP expression, and the intercellular transmission efficiency of HTLV-I between HCT-5 and TL-Su

As shown in Fig. 3a, the intracellular cAMP level was significantly lower in HCT-5 (2.67 ± 0.50 pmol/mL) than in TL-Su (11.58 ± 2.47 pmol/mL; $P = 0.0240$), although there was no significant difference in the intracellular cGMP levels between the cell lines (HCT-5, TL-Su; 5.02 ± 1.46, 4.86 ± 0.57 pmol/mL, respectively, $P = 0.9023$). Consistent with this result, VASP appeared to be less phosphorylated in HCT-5 than in TL-Su (Fig. 3b). Comparison of the intercellular transmission efficiency of HTLV-I showed that the relative luc activity was significantly higher in HCT-5 (7.1 ± 1.3) than that in TL-Su (1.1 ± 0.1; $P = 0.0156$). These data show the higher intercellular transmission efficiency of HTLV-1 of HCT-5 compared with that of TL-Su (Fig. 3c).

Discussion

In the present study, we showed that intracellular cAMP regulates the efficiency of intercellular transmission of HTLV-I through control of VASP phosphorylation in HTLV-I-infected cells. The present results suggested that the reorganization of actin, which is a major component of the cytoskeleton, plays an important role in HTLV-I transmission. However, the absence of any significant difference in


Figure 2 Effect of forskolin treatment on HCT-5 cells. (a) Treatment with 15 µmol/L forskolin for 90 min induced a significant increase in the intracellular cyclic adenosine monophosphate concentration (dimethyl sulfoxide [DMSO] treated, forskolin treated: 5.37 ± 0.47, 42.90 ± 0.95 pmol/mL, respectively). (b) Forskolin treatment gradually induced Ser[157] phosphorylation of vasodilator-stimulated phosphoprotein (VASP). However, there were no differences in the expression of human T-lymphotropic virus type I (HTLV-I) tax and gp46 between DMSO and forskolin treatment. (c) HCT-5 cells treated with 15 µmol/L forskolin for 90 min (5×10^5 cells) were co-cultivated for 6 h with H9/K30 *luc* cells (3.5×10^5 cells) in a 24-well culture plate at 37°C under 5% CO_2. The relative luc activity decreased to 50% in forskolin-treated HCT-5 cells (3.0 ± 0.5), compared with DMSO-treated HCT-5 cells (6.0 ± 0.9). Statistical significance was determined by Student's *t*-tests.

the intracellular cGMP concentrations between HCT-5 and TL-Su cells indicates that intracellular cGMP, which is also involved in VASP phosphorylation through PKG, does not influence the efficiency of HTLV-I transmission. To our knowledge, this is the first report of signaling molecule involvement in the efficacy of intercellular transmission of HTLV-I.

Figure 3 Comparative analysis of HCT-5 and TL-Su. (a) The intracellular cyclic adenosine monophosphate (cAMP) level was significantly lower in HCT-5 (2.67 ± 0.50 pmol/mL) than in TL-Su (11.58 ± 2.47 pmol/mL; P = 0.0240), although there was no significant difference in the intracellular cyclic guanosine monophosphate (cGMP) levels between both cell lines (HCT-5, TL-Su: 5.02 ± 1.46, 4.86 ± 0.57 pmol/mL, respectively, P = 0.9023). (b) Vasodilator-stimulated phosphoprotein (VASP) appeared to be less phosphorylated in HCT-5 than in TL-Su. (c) Comparison of the relative luc activity of HCT-5 and TL-Su. Either HCT-5 or TL-Su (5×10^5 cells) were co-cultivated for 6 h with H9/K30 *luc* cells (3.5×10^5 cells) in a 24-well culture plate at 37°C under 5% CO_2. The relative luc activity was significantly higher in HCT-5 cells (7.1 ± 1.3) than that in TL-Su cells (1.1 ± 0.1; P = 0.0156). Statistical significance was determined by Student's *t*-tests.

It is well known that a high HTLV-I proviral load in the peripheral blood is the most important prerequisite for the development of HAM/TSP.[13,14] Factors such as the relatively lower activity of HTLV-

I-specific CD8+ cytotoxic T cells against HTLV-I-infected CD4+ T cells[14] and the active replication of HTLV-I[15,16] have been proposed as reasons for the induction of high HTLV-I proviral load in HAM/TSP patients. However, the increased proliferation of HTLV-I-infected cells[3,17,18] seems to play a highly important role in this effect, and it can be speculated that efficient intercellular transmission of HTLV-I is also partially responsible. Indeed, we previously reported that HTLV-I production by HAM/TSP patient-derived HTLV-I-infected T-cell lines, in which Rac and Cdc42 are activated, is downregulated by blockade of integrin/ligand interactions[7], suggesting that the extracellular release of HTLV-I from these HTLV-I-infected T-cell lines depends on the reorganization status of the cytoskeleton after activation of integrin/ligand signaling. Therefore, HAM/TSP-derived HTLV-I-infected T-cell lines might have the activity of efficient intercellular transmission of HTLV-I. Indeed, in the present study, we showed that HCT-5 cells have the activity of efficient intercellular transmission of HTLV-I with downregulated p-VASP expression following downregulation of intracellular cAMP level compared with TL-Su cells. Although this observation requires confirmation in other HTLV-I-infected T-cell lines, it suggests that HTLV-I-infected cells in HAM/TSP patients have the potential for efficient transmission of HTLV-I to non-infected cells, and its potential is partially responsible for the induction of a high HTLV-I proviral load in the peripheral blood observed in HAM/TSP patients.

Interestingly, the intracellular cAMP concentration was found to be lower in an HTLV-I-infected T-cell line derived from an HAM/TSP patient than that in an HTLV-I carrier derived T-cell line. Recently, Kress et al. reported that cAMP levels are elevated by decreased expression of phosphodiesterase, which hydrolyzes the phosphodiester bond in cAMP, in HTLV-I-infected transformed T-cell lines derived from patients with adult T-cell leukemia.[19] Thus, the regulation of intracellular cAMP level might be different among HTLV-I-infected T-cell lines from HAM/TSP patients, HTLV-I carriers and adult T-cell leukemia patients.

The reorganization of actin is also involved in cell adhesion and migration.[20,21] We previously reported the increased adherent activity of peripheral blood CD4+ T cells of HAM/TSP patients to human endothelial cells.[22] Subsequently, we showed the heightened transmigrating activity of peripheral blood HTLV-I-infected T cells through a reconstituted basement membrane in HAM/TSP patients.[23] The low levels of intracellular cAMP in HTLV-I-infected

T cells in HAM/TSP patients might induce a tendency toward the reorganization of actin, thus accounting for the increased adhesion and transmigrating activities of HTLV-I-infected T cells in HAM/TSP patients.

In conclusion, we showed that the intracellular cAMP concentration regulates the efficiency of intercellular HTLV-I transmission through the regulation of VASP phosphorylation. Further investigations of the signaling molecules and pathways involved in the regulation of the intracellular cAMP concentrations in HTLV-I-infected T cells are required to elucidate the mechanisms underlying this effect. In addition, based on the results of a comparative study between HTLV-I-infected T-cell lines derived from an HAM/TSP patient and an HTLV-I carrier in the present study, comparative studies of peripheral blood HTLV-I-infected T cells in HAM patients and HTLV-I carriers are required to confirm our observations.

Acknowledgements

Competing interests

The authors declare that they have no competing interests.

References

1. Igakura T, Stinchcombe JC, Goon PK, et al. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. *Science*. 2003; **299**: 1713–6.

2. Barnard AL, Igakura T, Tanaka Y, Taylor GP, Bangham CRM. Engagement of specific T-cell surface molecules regulates cytoskeletal polarization in HTLV-1–infected lymphocytes. *Blood*. 2005; **106**: 988–95.

3. Pique C, Jones KS. Pathway of cell to cell transmission of HTLV-I. *Front Microbiol*. 2012; **3**: 378.

4. DeMali KA, Wennerberg K, Burridge K. Integrin signaling to the actin cytoskeleton. *Curr Opin Cell Biol*. 2003; **15**: 572–82.

5. Wittchen ES, van Buul JD, Burridge K, Worthylake RA. Trading spaces: Rap, Rac, and Rho as architects of transendothelial migration. *Curr Opin Hematol*. 2005; **12**: 14–21.

6. Etienne-Manneville S, Hall A. Integrin-mediated activation of Cdc42 controls cell polarity in migrating astrocytes through PKCζ. *Cell*. 2001; **106**: 489–98.

7. Fukushima N, Nakamura T, Nishiura Y, Ida H, Aramaki T, Eguchi K. HTLV-I production based on activation of integrin/ligand signaling in HTLV-I-infected T cell lines derived from HAM/TSP patients. *Intervirology*. 2008; **51**: 1234–9.

8. Harbeck B, Hüttelmaier S, Schlüter K, Jockusch BM, Illenberger S. Phosphorylation of the vasodilator-stimulated phosphoprotein regulates its interaction with actin. *J Biol Chem*. 2000; **275**: 30817–25.

9. Benz PM, Blume C, Seifert S, et al. Differential VASP phosphorylation controls remodeling of the actin cytoskeleton. *J Cell Sci*. 2009; **122**: 3954–65.

10. Yoshida A, Piroozmand A, Sakurai A, et al. Establishment of a biological assay system for human retroviral protease activity. *Microbes Infect*. 2005; **7**: 820–4.

11. Wakatsuki T, Schwab B, Thompson NC, Elson EL. Effects of cytochalasin D and latrunculin B on mechanical properties of cells. *J Cell Sci*. 2001; **114**: 1025–36.

12. Laurenza A, Sutkowski EM, Seamon KB. Forskolin: a specific stimulator of adenylyl cyclase or a diterpene with multiple sites of action? *Trends Pharmacol Sci*. 1989; **10**: 442–7.

13. Nagai M, Usuku K, Matsumoto W, et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. *J Neurovirol*. 1998; **4**: 586–93.

14. Jeffery KJ, Usuku K, Hall SE, et al. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. *Proc Natl Acad Sci USA*. 1999; **96**: 3848–53.

15. Yamano Y, Nagai M, Brennan M, et al. Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8 + T cells, and disease severity in HTLV-1-associated myelopathy (HAM/TSP). *Blood*. 2002; **99**: 88–94.

16. Asquith B, Mosley AJ, Heaps A, et al. Quantification of the virus-host interaction in human T lymphotropic virus I infection. *Retrovirology*. 2005; **2**: 75.

17. Wattel E, Vartanian JP, Pannetier C, Wain-Hobson S. Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy. *J Virol*. 1995; **69**: 2863–8.

18. Cavrois M, Leclercq I, Gout O, Gessain A, Wain-Hobson S, Wattel E. Persistent oligoclonal expansion of human T-cell leukemia virus type 1-infected circulating cells in patients with tropical spastic paraparesis/HTLV-1 associated myelopathy. *Oncogene*. 1998; **17**: 77–82.

19. Kress AK, Schneider G, Pichler K, Kalmer M, Fleckenstein B, Grassmann R. Elevated cyclic AMP levels in T

lymphocytes transformed by human T-cell lymphotropic virus type 1. *J Virol*. 2010; **84**: 8732–42.

20. Howe AK. Regulation of actin-based cell migration by cAMP/PKA. *Biochim Biophys Acta*. 2004; **1692**: 159–74.

21. Gardel ML, Schneider IC, Aratyn-Schaus Y, Waterman CM. Mechanical integration of actin and adhesion dynamics in cell migration. *Annu Rev Cell Dev Biol*. 2010; **26**: 315–33.

22. Ichinose K, Nakamura T, Nishiura Y, et al. Characterization of adherent T cells to human endothelial cells in patients with HTLV-I-associated myelopathy. *J Neurol Sci*. 1994; **122**: 204–9.

23. Furuya T, Nakamura T, Shirabe S, et al. Heightened transmigrating activity of CD4-positive T cells through reconstituted basement membrane in patients with human T-lymphotropic virus type I-associated myelopathy. *Proc Assoc Am Physicians*. 1997; **109**: 228–36.